Jan. 28, 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline-recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others.
The GeneStrat NGS test is paired with variant interpretation technology connected to a knowledge database developed by PierianDx. Physicians receive a streamlined report, including genomic insights, in a 72-hour turnaround time. The test is paid by Medicare under the National Coverage Determination for NGS Manual 90.2 section D by Novitas Solutions.
The company also announced the launch of its IQLung Treatment Guidance Testing Strategy. It includes the GeneStrat NGS and provides a broader view of a patient’s disease state. The testing strategy also includes blood-based proteomic and genomic testing workflows for early and advanced stage lung cancer that can aid physicians in making treatment decisions. Biodesix plans to add tests, which are in development, to the IQLung portfolio.